{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T16:29:30Z","timestamp":1784219370236,"version":"3.55.0"},"reference-count":115,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.semarthrit.2017.03.008","type":"journal-article","created":{"date-parts":[[2017,3,22]],"date-time":"2017-03-22T14:12:20Z","timestamp":1490191940000},"page":"183-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis"],"prefix":"10.1016","volume":"47","author":[{"given":"Fabrizio","family":"Cantini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Niccoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Nannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Cassar\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Kaloudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ennio","family":"Giulio Favalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Becciolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Benucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Li","family":"Gobbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Guiducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Foti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mosca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Goletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2017.03.008_bib1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.semarthrit.2015.10.001","article-title":"Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis","volume":"45","author":"Cantini","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib2","first-page":"523","article-title":"Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases","volume":"55","author":"Souto","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib3","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/art.30117","article-title":"Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor \u03b1 therapy: results from the nationwide Danish DANBIO registry","volume":"63","author":"Glintborg","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib4","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1136\/annrheumdis-2012-201933","article-title":"Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor \u03b1 inhibitor therapy: results from the Danish nationwide DANBIO registry","volume":"72","author":"Glintborg","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib5","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s10067-015-2929-7","article-title":"Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL","volume":"34","author":"Faf\u00e1","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"Suppl. 1","key":"10.1016\/j.semarthrit.2017.03.008_bib6","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1002\/ddr.21192","article-title":"Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides","volume":"75","author":"Biggioggero","year":"2014","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib7","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib9","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib10","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1136\/ard.2008.098111","article-title":"When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?","volume":"67","author":"Smolen","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib11","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/ard.2006.068304","article-title":"Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study","volume":"66","author":"Furst","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib12","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","article-title":"Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial","volume":"374","author":"Smolen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib13","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13075-015-0516-6","article-title":"Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor \u03b1 inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study","volume":"17","author":"Smolen","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s13075-015-0841-9","article-title":"Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population","volume":"17","author":"Weinblatt","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib15","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1016\/S0140-6736(16)31651-8","article-title":"Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib16","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar1881","article-title":"Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period","volume":"8","author":"Gomez-Reino","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib17","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.autrev.2009.12.010","article-title":"Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry","volume":"9","author":"Caporali","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/ard.2006.058776","article-title":"Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects","volume":"66","author":"Iannone","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib19","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s10067-011-1779-1","article-title":"Outcomes of switching anti-TNF drugs in rheumatoid arthritis\u2014a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN)","volume":"30","author":"Virkki","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib20","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/annrheumdis-2013-204714","article-title":"Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register","volume":"74","author":"Chatzidionysiou","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib21","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/rheumatology\/kem091","article-title":"Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice","volume":"46","author":"Bombardieri","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.22331","article-title":"Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study","volume":"56","author":"Hyrich","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib23","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/rheumatology\/kel054","article-title":"Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody","volume":"45","author":"Solau-Gervais","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib24","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/rheumatology\/ken034","article-title":"Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register","volume":"47","author":"Karlsson","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib25","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1136\/ard.2006.054742","article-title":"Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?","volume":"66","author":"Hjardem","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib26","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/ar3249","article-title":"Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-\u03b1 inhibitors","volume":"13","author":"Rendas-Baum","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib27","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jbspin.2015.01.021","article-title":"Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers","volume":"82","author":"Lequerr\u00e9","year":"2015","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib28","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1136\/annrheumdis-2013-203435","article-title":"Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib29","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib30","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib31","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti\u2013tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib32","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/ard.2007.085787","article-title":"Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies","volume":"68","author":"Keystone","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib33","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jama.2016.13512","article-title":"Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial","volume":"316","author":"Gottenberg","year":"2016","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib34","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1136\/annrheumdis-2011-200490","article-title":"Comparative effectiveness and safety of biological treatment options after tumour necrosis factor \u03b1 inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis","volume":"71","author":"Schoels","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib35","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1093\/rheumatology\/kes217","article-title":"The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review","volume":"51","author":"Moots","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib36","first-page":"191","article-title":"Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNF\u03b1 blocker failure","volume":"6","author":"Kekow","year":"2012","journal-title":"Biologics"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib37","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/art.22520","article-title":"B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents","volume":"56","author":"Finckh","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib38","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3109\/03009742.2012.729607","article-title":"Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort","volume":"42","author":"Chatzidionysiou","year":"2013","journal-title":"Scand J Rehabil Med"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib39","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/acr.21663","article-title":"Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register","volume":"64","author":"Soliman","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib40","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.3899\/jrheum.101324","article-title":"Effectiveness of a third tumor necrosis factor-\u03b1-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis","volume":"38","author":"Blom","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib41","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2013-203993","article-title":"Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study","volume":"74","author":"Emery","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib42","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1136\/annrheumdis-2012-201324","article-title":"Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study","volume":"71","author":"Gomez-Reino","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib43","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13075-015-0630-5","article-title":"Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial","volume":"17","author":"Manders","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib44","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/rheumatology\/keu158","article-title":"Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies","volume":"53","author":"Favalli","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib45","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s10067-015-3066-z","article-title":"Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry","volume":"34","author":"Rotar","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib46","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s10067-015-2879-0","article-title":"Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice","volume":"34","author":"Backhaus","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib47","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/annrheumdis-2013-203936","article-title":"The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor","volume":"74","author":"Harrold","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib48","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s10067-014-2711-2","article-title":"Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies","volume":"33","author":"Hirabara","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib49","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/14397595.2014.953668","article-title":"Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate","volume":"25","author":"Kobayakawa","year":"2015","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib50","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/annrheumdis-2013-204417","article-title":"Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy","volume":"73","author":"Das","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib51","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/1756-185X.12845","article-title":"Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study","volume":"19","author":"Pascart","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib52","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.autrev.2015.05.010","article-title":"Measuring psoriatic disease in clinical practice. An expert opinion position paper","volume":"14","author":"Lubrano","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib53","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/nrrheum.2016.183","article-title":"Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations","volume":"12","author":"Gossec","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib54","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/rheumatology\/ket187","article-title":"The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics","volume":"52","author":"Coates","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib55","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib56","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.3899\/jrheum.140876","article-title":"Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review","volume":"41","author":"Acosta Felquer","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib57","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib58","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib59","first-page":"883","article-title":"Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials","volume":"35","author":"Saad","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib60","series-title":"Drug Therapy for\u00a0Psoriatic Arthritis\u00a0in Adults: Update of a 2007 Report [Internet]","author":"Donahue","year":"2012"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib61","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/jcpt.12045","article-title":"Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in\u00a0psoriatic arthritis","volume":"38","author":"F\u00e9nix-Caballero","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib62","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00296-014-3006-2","article-title":"Treatment of psoriatic arthritis\u00a0with\u00a0anti-TNF\u00a0agents: a systematic review and meta-analysis of efficacy, effectiveness and safety","volume":"34","author":"Lemos","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib63","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/ard.2008.092767","article-title":"Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)","volume":"68","author":"Mease","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib64","first-page":"712","article-title":"Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept","volume":"33","author":"Mease","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib65","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3899\/jrheum.100698","article-title":"Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial","volume":"38","author":"Gladman","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib66","first-page":"869","article-title":"Two-year efficacy and safety of infliximab\u00a0treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)","volume":"35","author":"Antoni","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib67","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1136\/annrheumdis-2013-204902","article-title":"Clinical efficacy, radiographic and safety findings through 5\u2005years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib68","doi-asserted-by":"crossref","first-page":"e000119","DOI":"10.1136\/rmdopen-2015-000119","article-title":"Effect of certolizumab pegol over 96\u2005weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure","volume":"1","author":"Mease","year":"2015","journal-title":"RMD Open"},{"issue":"12","key":"10.1016\/j.semarthrit.2017.03.008_bib69","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/acr.22645","article-title":"Maintenance of clinical efficacy and radiographic benefit through 2 years of ustekinumab therapy in patients with active psoriatic arthritis: Results from the PSUMMIT 1 trial","volume":"67","author":"Kavanaugh","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib70","article-title":"Secukinumab for long-term treatment of psoriatic arthritis: 2-year follow-up from a phase 3, randomized, double-blind, placebo-controlled study","author":"Kavanaugh","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib72","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar1881","article-title":"Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period","volume":"8","author":"Gomez-Reino","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib73","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/ard.2007.073544","article-title":"Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register","volume":"67","author":"Kristensen","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib74","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/art.23333","article-title":"The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study","volume":"59","author":"Heiberg","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib75","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/ar2670","article-title":"Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register","volume":"11","author":"Saad","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib76","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1136\/annrheumdis-2012-203018","article-title":"Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study","volume":"72","author":"Fagerli","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib77","doi-asserted-by":"crossref","DOI":"10.1002\/acr.22788","article-title":"Eight-year retention rate of first-line tumor necrosis factor inhibitors in spondyloarthritis: a multi-center retrospective analysis","author":"Favalli","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib78","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/annrheumdis-2012-202347","article-title":"The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study","volume":"73","author":"Fagerli","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib79","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3109\/03009742.2014.962081","article-title":"Two-year survival rates of anti-TNF-\u03b1 therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA","volume":"44","author":"Iannone","year":"2015","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib80","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.semarthrit.2007.07.003","article-title":"Sustained clinical response and high infliximab survival in psoriatic arthritis patients: a 3-year long-term study","volume":"37","author":"Voulgari","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib81","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.semarthrit.2010.07.004","article-title":"Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study","volume":"40","author":"Saougou","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib82","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3899\/jrheum.100698","article-title":"Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial","volume":"38","author":"Gladman","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib83","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7861\/clinmedicine.14-1-95","article-title":"Effectiveness of switching between biologics in psoriatic arthritis- results of a large regional survey","volume":"14","author":"Jani","year":"2014","journal-title":"Clin Med"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib84","doi-asserted-by":"crossref","first-page":"862969","DOI":"10.1155\/2014\/862969","article-title":"Drug retention rates and treatment discontinuation among anti-TNF-\u03b1 agents in psoriatic arthritis and ankylosing spondylitis in clinical practice","volume":"2014","author":"Fabbroni","year":"2014","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib85","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/art.37876","article-title":"Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor \u03b1 inhibitor therapy: results from the Danish Nationwide DANBIO Registry","volume":"65","author":"Glintborg","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib86","doi-asserted-by":"crossref","first-page":"R117","DOI":"10.1186\/ar3054","article-title":"Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy","volume":"12","author":"Rudwaleit","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib87","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib88","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in Patients with Active Noninfectious Uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib89","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.3899\/jrheum.140879","article-title":"Comprehensive treatment of dactylitis in psoriatic arthritis","volume":"41","author":"Rose","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib90","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3899\/jrheum.140878","article-title":"Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis","volume":"41","author":"Orbai","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib91","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/art.22236","article-title":"Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study","volume":"55","author":"Cantini","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib92","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/ar592","article-title":"Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-a therapy and other novel approaches","volume":"4","author":"Braun","year":"2002","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib93","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1186\/ar4258","article-title":"The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients","volume":"15","author":"Plasencia","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib94","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1136\/annrheumdis-2012-202220","article-title":"The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis","volume":"72","author":"Garces","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib95","doi-asserted-by":"crossref","first-page":"R72","DOI":"10.1186\/ar1941","article-title":"Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER","volume":"8","author":"Carmona","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib96","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/rheumatology\/kev001","article-title":"Drug survival of anti-tumour necrosis factor \u03b1 therapy in spondyloarthropathies: results from the Spanish emAR II Study","volume":"54","author":"Rosales-Alexander","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib97","first-page":"2183","article-title":"Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data","volume":"32","author":"Delaunay","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib98","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar1881","article-title":"Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four year period","volume":"8","author":"Gomez-Reino","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib99","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/rheumatology\/ken094","article-title":"Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis","volume":"47","author":"Coates","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib100","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/ard.2007.073569","article-title":"Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period","volume":"66","author":"Conti","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib101","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/rheumatology\/ket249","article-title":"Remission in ankylosing spondylitis treated with anti-TNF-\u03b1 drugs: a national multicentre study","volume":"52","author":"Spadaro","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib102","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/ard.2010.131797","article-title":"Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NORDMARD register","volume":"70","author":"Lie","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib103","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/rheumatology\/keq377","article-title":"Efficacy in current practice of switching between anti-tumour necrosis factor-a agents in spondyloarthropathies","volume":"50","author":"Paccou","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib104","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/rheumatology\/ken334","article-title":"Switching anti-TNF therapy in ankylosing spondylitis","volume":"47","author":"Pradeep","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl. 1","key":"10.1016\/j.semarthrit.2017.03.008_bib105","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1007\/s10198-014-0598-0","article-title":"Real-life experience with switching TNF-\u03b1 inhibitors in ankylosing spondylitis","volume":"15","author":"Gulyas","year":"2014","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib106","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Baeten","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib107","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib108","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1136\/ard.61.11.994","article-title":"Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women\u05f3s Health Study","volume":"61","author":"Mikuls","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib109","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.autrev.2012.06.008","article-title":"Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry","volume":"12","author":"Atzeni","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"Suppl. 1","key":"10.1016\/j.semarthrit.2017.03.008_bib110","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1080\/14740338.2016.1240783","article-title":"Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis","volume":"15","author":"Minozzi","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib111","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.semarthrit.2012.04.001","article-title":"Risk of significant infection in rheumatoid arthritis patients switching anti-tumor necrosis factor-\u03b1 drugs","volume":"42","author":"Nguyen-Khoa","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib112","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.semarthrit.2012.12.024","article-title":"Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis","volume":"43","author":"Johnston","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib113","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1136\/ard.2010.146365","article-title":"The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents","volume":"70","author":"Curtis","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.semarthrit.2017.03.008_bib114","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1080\/14740338.2016.1218469","article-title":"Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis","volume":"15","author":"Tocci","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"Suppl. 1","key":"10.1016\/j.semarthrit.2017.03.008_bib115","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1080\/14740338.2016.1238458","article-title":"Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis","volume":"15","author":"Bonovas","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.semarthrit.2017.03.008_bib116","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/rheumatology\/keu358","article-title":"Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort","volume":"54","author":"Bluett","year":"2015","journal-title":"Rheumatology (Oxford)"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217300628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217300628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T05:15:34Z","timestamp":1719119734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017217300628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":115,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0049017217300628"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2017.03.008","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2017.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}